Vicore Pharma Holding AB (publ) at the annual general meeting held on 7 May 2024 approved the election of Yasir Al-Wakeel and Ann J. Barbier as members of the board of directors for the period until the end of the next annual general meeting. Hans Schikan was elected as the new chairman of the board of directors. Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy.

He was previously CEO of Prosensa, a company developing therapies for rare diseases including Duchenne muscular dystrophy acquired by BioMarin. He is also co-founder and Vice-Chair of Pharvaris, a clinical stage company developing therapies for the rare disease hereditary angioedema. Prior to Pharvaris and Prosensa, Hans Schikan was an executive at rare disease pioneer Genzyme.

He also served on the boards of Wilson Therapeutics, acquired by Alexion, Therachon, acquired by Pfizer, and VectivBio, acquired by Ironwood. Ann Barbier, MD, PhD, has more than 20 years of experience in drug discovery and development in rare diseases, including rare respiratory diseases She previously served as Chief Medical Officer of Translate Bio, a biotechnology company developing drugs for rare respiratory diseases acquired by Sanofi as well as Chief Medical Officer at CAMP4 Therapeutics. Yasir Al-Wakeel is a leader in biotech strategic finance and business development.

He is currently the CEO of a private biotech company and member of the Maxcyte board. Yasir Al-Wakeel was previously the Chief Financial Officer and Head of Corporate Development at Kronos Bio, Chief Financial and Strategy Officer at Neon Therapeutics, acquired by BioNTech, and Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, leading its 1 billion USD asset sale to Ipsen.